Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Ron Filler
Advertisement
Ron Filler, PhD, president and CEO, Drug Development Consultants
Articles by Ron Filler
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: Roller-Compacted Formulations
2
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
3
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
4
AAPS PharmSci 360 2026: AI in Drug Delivery
5